Best Small Cap Stocks to Trade

Small Cap Stock Alerts in Real Time | No one provides consistent winners like Broad Street!

Feb 21 2017

Cannabis Science Inc (OTC PINK: CBIS) Cannabis Report

About Broad Street Alerts:

Big Opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

 

January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

 

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone.

Broad Street Alerts Mission Statement

We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm. Please read our privacy policy and full disclaimer below.

 

CBIS Report:

 

Cannabis Science, Inc. has the advantage of unparalleled understanding of metabolic processes enabling it to provide innovative treatment options for medical needs, which are currently unmet.Cannabis has been used for thousands of years and currently there are many scientific publications, which provide evidence of the underlying effect on biochemical pathways. The company uses an innovative approach approach to discover to develop cannabinoid-based therapies to improve the lives of patients. It is dedicated to working closely with regulatory agencies to provide patients with access to high quality, first class cannabinoid pharmaceutical, especially for patients critically in need by using clinical trial material comes from the highest quality cultivation and production facilities. The products fall into the broad categories of medical cannabinoid formulations which are developed from one or more of the compounds extracted from the cannabis plant. The immediate focus is on the treatment of cancer which is one of the most important diseases globally .

In 2013, the company submitted a patent application in Europe, the subject of which is development of formulations based on cannabinoids to treat a range of neuro behavioural disorders. Cannabis plants have been extensively used in medical and agricultural applications for thousands of years. Some applications of cannabinoids include the used for the alleviation of nausea and the stimulation of appetite for patients suffering from AIDS and cancer. Other uses include the treatment of chronic pain and the reduction of muscle spasms caused by multiple sclerosis and injuries to the spinal cord. The company is long established in the use of cannabis.

The team of scientists at the company are focused on producing on commercialising products based on botanical extracts from cannabis as new uses continue to develop. For instance, scientists have recently discovered that topical preparations based on cannabinoids can be effective for treatment of MRSI, which is a deadly flesh eating disease resistant to antibiotics. Other topical applications are used to treat localised pain as in the treatment of arthritis and burns as well as neuropathic pain for which there are few effective alternative treatments. It is becoming increasingly evident that based on needs, which are self identified, around 2% of the Canadian adult population is already using cannabinoids for medicinal purposes and this is likely to become a multibillion dollar industry in the near future.

The investment potential

This pioneering biotech company has already created extract formulations based on cannabinoids for different medical conditions such as more than eight different types of cancer. Each of these formulations has the potential to bring in revenues and earnings in the hundreds and millions of dollars, especially when they are combined with NutraSweet fruit products and a strategic partnership with MedBox solutions. The market for cannabinoids is estimated at $ 30 billion-$ 50 billion and could be, according to internal estimates, has much as $ 75 billion, based on the Federal Medical Cannabis Program in 2017. This is the first publicly traded cannabinoid company involved in formulations based on cannabinoids extracts. The business model and leadership position could have plenty of investment business potential over the next couple of decades and the company could be potentially a billion-dollar biotech global leader. There could potentially be hundreds of millions of patients suffering from chronic pain, cancer, MS, PSTD and other terminal illnesses.

Recent developments

Crown Baus Capital Corp.(OTC PINK: CBCA), is a global conglomerate looking to capitalize on its key industry strengths. The team at the company are structuring investment opportunity with Cannabis Science for participation in a property and drug development project in Douglas County, Nevada. Cannabis Science has substantial property development contracts to build fully licensed facilities for cannabis and hemp production, which are fully state compliant and the investment opportunities are being divided into one acre parcels for each land development project. The objective is to build a portfolio of investors, partners and supply chain operators throughout the United States, which are in various stages of development. Cannabis Science has announced the beginning of a buildup of a cannabis drug development facility in Douglas County, Nevada, of which the first phase is approximately 33,000 ft.² of greenhouse space for every one acre plot. The first phase for each built out of one acre will cost between USD 300,000 and USD 500,000.

The bottom line

The company currently trades at a market valuation of around $ 280 million though it has little by way of assets or revenues and a rising short-term debt. However, the potential for this small cap stock is exciting for investors. The way has been prepared for the commercialisation of cannabis formulations without the necessity of the rigourous FDA approvals and the future could be promising. Though the company would require to use the normal procedures for producing a blockbuster pharmaceutical product, it is a cannabis company in right space and the stock could be a good way of playing the potential of the cannabis industry generally.

 

 

 

Broad Street Alerts has not been compensated for this report by anyone and the opinions if any are that of the author Ramakrishnan Iyar. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

Written by broadAdmin · Categorized: Uncategorized

Privacy Policy and Disclaimer

Transparency is very important to us.

Please view our full privacy policy and disclaimer below.

 

 

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.
Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
Disclaimer
BroadStreetAlerts. com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
This website / media webpage is owned, operated, and edited by Small Cap Specialists LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “SCS LLC” refers to Small Cap Specialists LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. SCS LLC’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.
Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s , owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.
All information on featured companies is provided by the companies profiled or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
SCS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
SCS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

 

Most Publicly Traded Companies Engage in Some Form of Paid Media, Investor Relations and Advertising. 

Copyright © 2023 · Broad Street Alerts · All Rights Reserved

Manage Cookie Consent
We use cookies to optimize our website and your experience.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}